ASP4058

S1P receptor agonist selective for S1P1 and S1P5; structure in first source

Also Known As:

5-(3-(trifluoromethyl)-4-(((2S)-1,1,1-trifluoropropan-2-yl)oxy)phenyl)-1,2,4-oxadiazol-3-yl)-1H-benzimidazole

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2014 - "Oral administration of ASP4058 reduced the number of peripheral lymphocytes and inhibited the development of experimental autoimmune encephalomyelitis (EAE) in Lewis rats. " 01/01/2014 - "ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile."
2.	Multiple Sclerosis 01/01/2014 - "These observations suggest that ASP4058 represents a new therapeutic option for treating multiple sclerosis that is safer than nonselective S1P receptor agonists such as fingolimod. "
3.	Intracranial Aneurysm (Cerebral Aneurysm) 01/01/2017 - "A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration."
4.	Bradycardia 01/01/2014 - "Although these immunomodulatory effects were comparable to those of fingolimod, ASP4058 showed a wider safety margin than fingolimod for bradycardia and bronchoconstriction in rodents. "

1.	sphingosine 1-phosphate (sphingosine-1-phosphate)
2.	Sphingosine-1-Phosphate Receptors
3.	Fingolimod Hydrochloride (FTY720)

1.	Oral Administration